Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AKS-452 anti-COVID-19 phase I/II vaccination study
NL-OMON51213Phase 2Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Apr 2021
- Modality
- Vaccines & Immunotherapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of AKS-452 in coronavirus disease 2019 (COVID-19) (5 arms), sponsored by University Medical Center Groningen. Primary endpoints: Phase I safety, Phase I immunogenicity and 2 more. Started Apr 2021; status: active, not recruiting.
02
Drugs
AKS-452
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON51213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51213.